Clinical Trials Logo

Clinical Trial Summary

The purpose of this open-label study is to evaluate the safety and efficacy of cobimetinib in extracranial AVM.


Clinical Trial Description

After being informed of the study and potential risks, all patients giving informed consent will go undergo a screening period to determine eligibility for study entry. Patients who meet the eligibility requirements will be given cobimetinib to take by mouth once daily at the same time each day for 21 days and then have 7 days with no treatment. Patients will receive cobimetinib as a tablet (adult) or as a liquid (child). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05125471
Study type Interventional
Source University of Arkansas
Contact Joana M Mack, MD
Phone 501-364-1494
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 2022
Completion date December 2023